These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7489345)

  • 1. Comparative study of two high doses of lymphoblastoid interferon in the treatment of chronic hepatitis C: influence on the levels of ALT, viraemia and histologic activity.
    Enríquez J; Torras X; Miralles F; Martinez Cerezo FJ; Sancho Poch FJ; Buenestado J; Madoz P; Howe I; Vilardell F
    J Viral Hepat; 1995; 2(4):181-7. PubMed ID: 7489345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphoblastoid interferon therapy in chronic hepatitis C: biochemical, virological and histological evaluation of two different doses.
    Picciotto A; Callea F; Varagona G; Bardellini E; Borzone S; De Conca V; Vallarino E; Giudici-Cipriani A; Vitali A; Grasso A
    Liver; 1995 Feb; 15(1):20-4. PubMed ID: 7776853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.
    Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M
    J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose increase augments response rate to interferon-alpha in chronic hepatitis C.
    Ferenci P; Stauber R; Propst A; Fiedler R; Müller C; Gschwantler M; Schütze K; Datz C; Judmaier G; Vogel W; Krejs GJ; Gangl A
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):103S-108S. PubMed ID: 9011466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-alpha therapy.
    Shindo M; Arai K; Sokawa Y; Okuno T
    Ann Intern Med; 1995 Apr; 122(8):586-91. PubMed ID: 7887552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection.
    Weiland O; Chen M; Lindh G; Mattsson L; Schvarcz R; Sönnerborg A; Wahl M; Wejstål R; Widell A; Norkrans G
    Scand J Infect Dis; 1995; 27(5):319-24. PubMed ID: 8588128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
    Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
    Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised trial of lymphoblastoid alpha-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia.
    Camps J; Castilla A; Ruiz J; Civeira MP; Prieto J
    J Hepatol; 1993 Mar; 17(3):390-6. PubMed ID: 8391042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C viraemia rebound after "successful" interferon therapy in patients with chronic non-A, non-B hepatitis.
    Garson JA; Brillanti S; Ring C; Perini P; Miglioli M; Barbara L
    J Med Virol; 1992 Jul; 37(3):210-4. PubMed ID: 1279110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with interferon-alpha2b of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. The North West Italian Hepatological Group.
    Saracco G; Ciancio A; Ghisetti V; Rocca G; Cariti G; Andreoni M; Tabone M; Roffi L; Calleri G; Ballaré M; Terreni N; Sartori M; Tappero GF; Traverso A; Poggio A; Orani A; Maggi G; Di Napoli A; Arrigoni A; Rizzetto M;
    Eur J Gastroenterol Hepatol; 2001 Feb; 13(2):149-55. PubMed ID: 11246614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks.
    Reichard O; Foberg U; Frydén A; Mattsson L; Norkrans G; Sönnerborg A; Wejstål R; Yun ZB; Weiland O
    Hepatology; 1994 Feb; 19(2):280-5. PubMed ID: 7507462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The fluctuations of hepatitis C virus RNA and IgM anti-HCV (core) serum levels correlate with those of alanine aminotransferases during the hepatitis relapses of patients treated with interferon.
    Negro F; Abate ML; Mondardini A; Baldi M; Leandro G; Lombardi S; Wolfe L; Ryff JC; Verme G; Brunetto MR
    J Viral Hepat; 1995; 2(4):171-4. PubMed ID: 7489343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose.
    Shiffman ML; Hofmann CM; Luketic VA; Sanyal AJ; Contos MJ; Mills AS
    Hepatology; 1996 Jul; 24(1):21-6. PubMed ID: 8707264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes of serum hepatitis C virus levels in patients with chronic hepatitis C treated with two courses of interferon administration.
    Saitoh Y; Miura M; Niitsuma H; Numata N; Ohori H; Ishii M; Toyota T
    Tohoku J Exp Med; 1994 Aug; 173(4):361-9. PubMed ID: 7529950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver iron influences the response to interferon alpha therapy in chronic hepatitis C.
    Fargion S; Fracanzani AL; Sampietro M; Molteni V; Boldorini R; Mattioli M; Cesana B; Lunghi G; Piperno A; Valsecchi C; Fiorelli G
    Eur J Gastroenterol Hepatol; 1997 May; 9(5):497-503. PubMed ID: 9187884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term carriage of hepatitis C virus with normal aminotransferase after interferon treatment in patients with chronic hepatitis C.
    Kakumu S; Yoshika K; Tanaka K; Higashi Y; Kurokawa S; Hirofuji H; Kusakabe A
    J Med Virol; 1993 Sep; 41(1):65-70. PubMed ID: 8228941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum.
    Ampurdanés S; Olmedo E; Maluenda MD; Forns X; López-Labrador FX; Costa J; Sánchez-Tapias JM; de Anta MT; Rodés J
    J Hepatol; 1996 Dec; 25(6):827-32. PubMed ID: 9007709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group.
    Chemello L; Cavalletto L; Casarin C; Bonetti P; Bernardinello E; Pontisso P; Donada C; Belussi F; Martinelli S; Alberti A
    Ann Intern Med; 1996 Jun; 124(12):1058-60. PubMed ID: 8633819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HCV-RNA levels play an important role independently of genotype in predicting response to interferon therapy.
    Picciotto A; Campo N; Brizzolara R; Sinelli N; Poggi G; Grasso S; Celle G
    Eur J Gastroenterol Hepatol; 1997 Jan; 9(1):67-9. PubMed ID: 9031902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum HCV RNA levels in patients with chronic hepatitis C given a second course of interferon alpha-2b treatment after relapse following initial treatment.
    Weiland O; Zhang YY; Widell A
    Scand J Infect Dis; 1993; 25(1):25-30. PubMed ID: 8384732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.